COMPANY PROFILE

iOnctura

Explore full profile

Oncology therapies countering immunosuppression in tumors

Geneva, SwitzerlandFounded 2017Biotech & Life Sciences

Valuation $250–500M Last recorded · 2024

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About iOnctura

Developer of next-generation bio-molecules intended for the treatment of cancer and fibrosis. The company's bio-molecules include novel therapeutics that modulate key culprits of immunosuppression in the tumor microenvironment, enabling doctors to treat diseases such as cancer faster. Keywords: Healthcare Devices, Services, Supplies, Biomolecule Drugs, Biopharmaceutical Research, Cancer Drug, Cancer Treatment, Fibrotic Diseases Drugs, Oncology Treatment.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2017
Headquarters: Geneva, Switzerland
Employees: 34
Open positions: None listed
Dealroom signal: 78.8/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Immune System, Spinout, EIC, Biotech and Pharma, EIC Fund, Woman Founder, Horizon Europe
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

10 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES BOther financing	Jun 2024	$88M	$352M	VI Partners · 3B Future Health Fund · Merck Ventures · Schroders Capital	↗
GRANTOther financing	May 2024	$404K	—	KWF Kankerbestrijding	↗

Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

iOnctura website traffic

Latest recorded traffic for iOnctura is 80 monthly website visits, down 55.6% over the last three months. iOnctura's team grew 9.7% over the past year.

Latest monthly visits80 3-month web change-55.6% 1-year team growth+9.7%

Monthly website visitsNov 2016–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
NPNETRIS PharmaMonoclonal antibodies overcoming cancer therapy resistance.	Lyon, France	Operational	20	$20M	$33M
REResistellOffers an alternative to culture-based antibiogram, the gold standard in antibiotic susceptibility testing (AST)	Muttenz, Switzerland	Operational
TBTILT BiotherapeuticsTILT Bio aims to enable T-cell treatments and immune checkpoint inhibitors with oncolytic viruses, used to boost lymphocytes and immunological checkpoint blocking antibody treatments	Helsinki, Finland	Operational
ELEltheraBringing together experienced pharma and biotech executives with cutting-edge academic researchers to develop proprietary, first-in-class oncology drugs	Schlieren, Switzerland	Operational
XEXenotheraDeveloping improved immunological treatments using their glyco-humanized antibody platform	Nantes, France	Operational
PEPeptomycFoundational anti-MYC mini-proteins for cancer treatment	Barcelona, Spain	Operational
HEHEPHAISTOS-PharmaDeveloping Tomorrow’s immuno-oncology and modulator therapy \| A single platform for defeating cancer and much more	Orsay, France	Operational
ATAmal TherapeuticsDeveloping and progressing therapeutic cancer vaccines	Geneva, Switzerland	Acquired